Teva Pharma (TEVA) volatility flat into Mylan (MYL) granted FDA approval of Copaxone

Teva Pharma (TEVA) PT Lowered to $15 at Morgan Stanley

Morgan Stanley lowered its price target on Teva Pharma (NYSE: TEVA) to $15.00 (from $16.00) while maintaining a Underweight rating.

Teva Pharma (TEVA) PT Lowered to $21 at Barclays; Generic Copaxone 40mg Approval 'Will Offset Some Contracting Strategies... Hurt Sentiment'

Barclays lowered its price target on Teva Pharma (NYSE: TEVA) to $21.00 (from $23.00) while maintaining a Equalweight rating, following an update on the U.S. Specialty Pharmaceutical industry, as the FDA recently approved a generic Copaxone formulation.

Analyst Douglas Tsao notes a... More

Mylan (MYL) PT Raised to $36 at Cowen; Reiterates Market Perform

Cowen raised its price target on Mylan (NASDAQ: MYL) to $36.00 (from $30.00) while maintaining a Market Perform rating. Cowen updated its model to reflect a potential $800MM in generic Copaxone contribution in 2018, and then modestly declining with other competition.

With this approval the... More

Mylan (MYL) PT Raised to $45 at BTIG Following Copaxone Generic Approval

BTIG analyst Timothy Chiang raised his price target on Mylan (NASDAQ: MYL) to $45.00 (from $42.00) while maintaining a Buy rating after the company received final FDA approval for its generic versions of Tevas (NASDAQ: TEVA) 20mg and 40mg... More

Mylan's (MYL) Surprise Copaxone Generic Approval 'Quite Negative' for Teva Pharma (TEVA) - Mizuho

Mizuho analyst Irina Koffler weighed in on Mylan's (NASDAQ: MYL) surprise approval for generic Copaxone after downplaying the possibility of a September approval and taking Copaxone out of its 2017 estimates. Koffler sees the news as "quite negative" Teva Pharma (NYSE: TEVA).

On Mylan, Koffler notes, "Importantly, Copaxone is AP rated (or therapeutically equivalent and substitutable), which makes it easier to... More

Momenta Phama (MNTA) on Watch After Mylan (MYL) Granted FDA Approval of First Generic for Copaxone

Momenta Phama (NASDAQ: MNTA) shares were in focus after Mylan (Nasdaq: MYL) was granted FDA approval of the first generic for Copaxone. Shares declined pre-market, along with Teva Pharma (NYSE: TEVA).